Assembly Biosciences (NASDAQ:ASMB – Get Free Report) and RYTHM (NASDAQ:RYM – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.
Risk and Volatility
Assembly Biosciences has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, RYTHM has a beta of 9.46, meaning that its stock price is 846% more volatile than the S&P 500.
Profitability
This table compares Assembly Biosciences and RYTHM’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Assembly Biosciences | -0.06% | -0.02% | -0.02% |
| RYTHM | -6.20% | -12.57% | -2.60% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Assembly Biosciences | 1 | 0 | 4 | 1 | 2.83 |
| RYTHM | 1 | 0 | 0 | 0 | 1.00 |
Assembly Biosciences presently has a consensus target price of $47.50, suggesting a potential upside of 101.87%. Given Assembly Biosciences’ stronger consensus rating and higher probable upside, equities analysts clearly believe Assembly Biosciences is more favorable than RYTHM.
Institutional and Insider Ownership
19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 6.0% of RYTHM shares are held by institutional investors. 3.5% of Assembly Biosciences shares are held by insiders. Comparatively, 3.5% of RYTHM shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Assembly Biosciences and RYTHM”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Assembly Biosciences | $72.30 million | 6.63 | -$6.12 million | $1.02 | 23.07 |
| RYTHM | $17.28 million | 2.66 | -$33.26 million | ($10.53) | -2.00 |
Assembly Biosciences has higher revenue and earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Assembly Biosciences beats RYTHM on 14 of the 15 factors compared between the two stocks.
About Assembly Biosciences
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
About RYTHM
Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
